<article article-type="case-report" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="pmc-domain-id">2757</journal-id><journal-id journal-id-type="pmc-domain">cureus</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12863710</article-id><article-id pub-id-type="pmcid-ver">PMC12863710.1</article-id><article-id pub-id-type="pmcaid">12863710</article-id><article-id pub-id-type="pmcaiid">12863710</article-id><article-id pub-id-type="pmid">41635362</article-id><article-id pub-id-type="doi">10.7759/cureus.100708</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Hematology</subject></subj-group><subj-group><subject>Oncology</subject></subj-group><subj-group><subject>Gastroenterology</subject></subj-group></article-categories><title-group><article-title>Vanishing Bile Duct Syndrome as a Rare Complication of Classic Hodgkin's Lymphoma: A Case Report and Literature Review</article-title></title-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Muacevic</surname><given-names initials="A">Alexander</given-names></name></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Adler</surname><given-names initials="JR">John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Tai</surname><given-names initials="JW">Jody W</given-names></name><xref ref-type="aff" rid="aff-1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shah</surname><given-names initials="VD">Vivek D</given-names></name><xref ref-type="aff" rid="aff-2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Harmon</surname><given-names initials="RL">Rhett L</given-names></name><xref ref-type="aff" rid="aff-1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chandna</surname><given-names initials="S">Shaun</given-names></name><xref ref-type="aff" rid="aff-3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yan</surname><given-names initials="J">Jessica</given-names></name><xref ref-type="aff" rid="aff-2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fathizadeh</surname><given-names initials="P">Payman</given-names></name><xref ref-type="aff" rid="aff-4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Beaven</surname><given-names initials="S">Simon</given-names></name><xref ref-type="aff" rid="aff-3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Karunasiri</surname><given-names initials="D">Deepthi</given-names></name><xref ref-type="aff" rid="aff-4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="P">Phyllis</given-names></name><xref ref-type="aff" rid="aff-2">2</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Internal Medicine, Olive View University of California Los Angeles Medical Center, Los Angeles, USA </aff><aff id="aff-2">
<label>2</label>
Hematology and Oncology, Olive View University of California Los Angeles Medical Center, Los Angeles, USA </aff><aff id="aff-3">
<label>3</label>
Gastroenterology, Olive View University of California Los Angeles Medical Center, Los Angeles, USA </aff><aff id="aff-4">
<label>4</label>
Pathology, Olive View University of California Los Angeles Medical Center, Los Angeles, USA </aff><author-notes><corresp id="cor1">
Jody W. Tai <email>jtai@dhs.lacounty.gov</email>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>3</day><month>1</month><year>2026</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>1</month><year>2026</year></pub-date><volume>18</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">503563</issue-id><elocation-id>e100708</elocation-id><history><date date-type="received"><day>24</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>3</day><month>1</month><year>2026</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>03</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-04 09:25:12.630"><day>04</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>Copyright © 2026, Tai et al.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder>Tai et al.</copyright-holder><license><ali:license_ref content-type="ccbylicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="cureus-0018-00000100708.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><self-uri xlink:href="https://cureus.com/articles/377720-vanishing-bile-duct-syndrome-as-a-rare-complication-of-classic-hodgkins-lymphoma-a-case-report-and-literature-review" xmlns:xlink="http://www.w3.org/1999/xlink">This article is available from https://cureus.com/articles/377720-vanishing-bile-duct-syndrome-as-a-rare-complication-of-classic-hodgkins-lymphoma-a-case-report-and-literature-review</self-uri><abstract><p>Vanishing bile duct syndrome (VBDS) is an acquired condition of progressive intrahepatic bile duct loss, resulting in severe cholestasis. Here, we present a case of VBDS in a patient with newly diagnosed classic Hodgkin's lymphoma (cHL). Our patient presented with cholestatic liver test elevations, including bilirubin and alkaline phosphatase. Liver biopsy confirmed the paucity of bile ducts and did not show involvement by lymphoma. Though the exact pathophysiology is unclear, it is postulated to be driven by cytokine release and T-lymphocyte cell dysregulation. Our patient has made a remarkable, albeit incomplete, liver recovery with cHL-directed treatment. Given the poor prognosis and higher mortality rate of VBDS, a multidisciplinary approach involving oncology, hepatology, and prompt initiation of dose-adjusted chemotherapy is imperative.</p></abstract><kwd-group kwd-group-type="author"><kwd>abvd chemotherapy</kwd><kwd>acute liver failure (alf)</kwd><kwd>classic hodgkin lymphoma</kwd><kwd>paraneoplastic phenomenon</kwd><kwd>vanishing bile duct syndrome</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Vanishing bile duct syndrome (VBDS) is a syndrome of progressive destruction and loss of intrahepatic bile ducts leading to cholestasis. Presentations can range from asymptomatic to fulminant liver failure. Most commonly, VBDS arises within one to six months after a drug-induced liver injury, most commonly with antibiotics such as amoxicillin/clavulanic acid, fluoroquinolones, or trimethoprim-sulfamethoxazole, among others [<xref ref-type="bibr" rid="REF1">1</xref>]. In order to diagnose VBDS, alternate etiologies of biliary duct loss, such as primary biliary cholangitis, primary sclerosing cholangitis, and graft-versus-host disease, must be ruled out. The diagnosis is confirmed with a liver biopsy, which shows intralobular bile ductopenia with less than 50% of portal areas having a bile duct in an adequate biopsy specimen of at least 10 portal tracts [<xref ref-type="bibr" rid="REF1">1</xref>]. A paucity of reports has described VBDS associated with classic Hodgkin's lymphoma (cHL), with no consensus in the literature review on its incidence. The pathobiology is poorly understood but likely to be driven by hepatotoxic cytokines and thymocyte-lymphocyte (T-lymphocyte) dysregulation, leading to immunogenic damage to biliary ducts. Due to impaired liver function due to VBDS, treatment of the underlying disease is often challenging. Dose modifications can lead to undertreatment of the cHL, which is a highly treatable and curable disease. Standard of care with chemotherapy and radiation has resulted in high cure rates, with a greater than 80% five-year overall survival [<xref ref-type="bibr" rid="REF2">2</xref>]. In our patient, treatment adaptations have led to remarkable improvements in liver function in parallel with the response of the lymphoma. We add to the existing literature a case of cHL as the leading explanation for VBDS with ensuing cholestatic liver injury and provide a structured literature review to inform diagnostic and therapeutic decisions.</p></sec><sec sec-type="cases"><title>Case presentation</title><p>A 31-year-old male with no prior medical history presented to the emergency department for diffuse abdominal pain and diarrhea for one week. He reported one week of subjective fevers and three to four watery bowel movements daily. He also endorsed 20-pound weight loss and occasional night sweats over the prior six months and left-sided neck swelling over the prior four months. He denied any emesis, early satiety, dysphagia, odynophagia, melena, hematochezia, or dark-colored urine. There was no reported family history of liver disease. Social history was notable for working in construction and no tobacco, alcohol, or drug use.</p><p>Upon presentation, the patient’s temperature was 36.7 degrees Celsius, heart rate of 80 beats per minute, blood pressure of 112/66 millimeters of mercury (mmHg), and oxygen saturation of 99% on room air. Physical exam was significant for left-sided neck fullness without any palpable lymphadenopathy elsewhere. The patient was not noted to be jaundiced.</p><p>He was found to have leukopenia, thrombocytopenia, elevated liver tests, and coagulopathy. Laboratory investigations are summarized in Table <xref ref-type="table" rid="TAB1">1</xref>. Other relevant studies included a stool polymerase chain reaction (PCR) panel for infectious causes of diarrhea, a stool ova and parasite exam, and a stool acid-fast bacillus (AFB) exam. Liver injury workup included negative anti-nuclear antibody, anti-smooth muscle antibody, hepatitis panel, alpha-1 antitrypsin, and normal iron stores. At presentation, the R factor was 1.8, suggestive of a cholestatic pattern of injury.</p><table-wrap id="TAB1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Laboratory results on admission</title><p>WBC: white blood cell, Hgb: hemoglobin, LDH: lactate dehydrogenase, INR: international normalized ratio, AST: aspartate aminotransferase, ALT: alanine aminotransferase, GGT: gamma-glutamyl transferase</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Test</td><td colspan="1" rowspan="1">Result</td><td colspan="1" rowspan="1">Reference Range</td></tr><tr><td colspan="1" rowspan="1">WBC</td><td colspan="1" rowspan="1">4.3 K/cumm</td><td colspan="1" rowspan="1">4.5-10.0 K/cumm</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Hgb</td><td colspan="1" rowspan="1">12.8 g/dL</td><td colspan="1" rowspan="1">12.0-14.6 g/dL</td></tr><tr><td colspan="1" rowspan="1">Platelets</td><td colspan="1" rowspan="1">64 K/cumm</td><td colspan="1" rowspan="1">160-360 K/cumm</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Alkaline phosphatase</td><td colspan="1" rowspan="1">398 U/L</td><td colspan="1" rowspan="1">38-126 U/L</td></tr><tr><td colspan="1" rowspan="1">AST</td><td colspan="1" rowspan="1">68 U/L</td><td colspan="1" rowspan="1">15-41 U/L</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">ALT</td><td colspan="1" rowspan="1">234 U/L</td><td colspan="1" rowspan="1">14-54 U/L</td></tr><tr><td colspan="1" rowspan="1">Total bilirubin</td><td colspan="1" rowspan="1">6.4 mg/dL</td><td colspan="1" rowspan="1">0.1-1.2 mg/dL</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Direct bilirubin</td><td colspan="1" rowspan="1">4.2 mg/dL</td><td colspan="1" rowspan="1">0.1-0.4 mg/dL</td></tr><tr><td colspan="1" rowspan="1">GGT</td><td colspan="1" rowspan="1">90 U/L</td><td colspan="1" rowspan="1">7-50 U/L</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">HIV</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Hepatitis B</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Hepatitis C</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Anti-mitochondrial antibody</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Anti-smooth muscle antibody</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr></tbody></table></table-wrap><p>Computerized tomography (CT) of the neck was significant for enlarged, bulky cervical lymph nodes throughout the left, largest in the left neck measuring 5.2 x 2.7 x 4.1 centimeters (cm), as shown in Figure <xref ref-type="fig" rid="FIG1">1</xref>. </p><fig fig-type="figure" id="FIG1" orientation="portrait" position="anchor"><label>Figure 1</label><caption><title>Coronal view of CT neck</title><p>The red arrow highlights the left cervical lymphadenopathy.</p></caption><graphic orientation="portrait" position="float" xlink:href="cureus-0018-00000100708-i01.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><p>CT scan of the chest, abdomen, and pelvis revealed inflammatory changes in a section of the jejunum, as well as in the terminal ileum and colon, as seen in Figure <xref ref-type="fig" rid="FIG2">2</xref>.</p><fig fig-type="figure" id="FIG2" orientation="portrait" position="anchor"><label>Figure 2</label><caption><title>CT scan of the chest, abdomen, and pelvis with inflammatory changes in a section of the jejunum, as well as in the terminal ileum and colon</title><p>The red arrow points towards an area of mucosal enhancement with increased wall thickness.</p></caption><graphic orientation="portrait" position="float" xlink:href="cureus-0018-00000100708-i02.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><p>The right upper quadrant ultrasound was consistent with hepatomegaly and a contracted gallbladder, as seen in Figure <xref ref-type="fig" rid="FIG3">3</xref>.</p><fig fig-type="figure" id="FIG3" orientation="portrait" position="anchor"><label>Figure 3</label><caption><title>Ultrasound of the liver from the long axis showing hepatomegaly</title><p>The red arrow points towards contracted gallbladder.</p></caption><graphic orientation="portrait" position="float" xlink:href="cureus-0018-00000100708-i03.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><p>Magnetic resonance cholangiopancreatography (MRCP) demonstrated normal bile ducts and a patent biliary tree without evidence of strictures, masses, or biliary filling defects; there was no evidence of primary sclerosing cholangitis, as seen in Figure <xref ref-type="fig" rid="FIG4">4</xref>. </p><fig fig-type="figure" id="FIG4" orientation="portrait" position="anchor"><label>Figure 4</label><caption><title>MRCP showing normal bile ducts and a red arrow pointing towards a patent biliary tree without evidence of strictures, masses, or biliary filling defects</title><p>MRCP: magnetic resonance cholangiopancreatography</p></caption><graphic orientation="portrait" position="float" xlink:href="cureus-0018-00000100708-i04.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><p>Gastroenterology was consulted and performed an endoscopy with colonoscopy that revealed patchy colonic inflammation with ulcerations and erythema in the ascending and transverse colon, with biopsies showing active inflammation without granulomas or lymphomatous involvement. Enteroscopy demonstrated mild gastropathy and diffuse erythema, edema, and ulcerations throughout the duodenum and jejunum, which were biopsied to evaluate for <italic toggle="yes">Helicobacter pylori </italic>and rule out Crohn’s disease. Biopsies and staining were negative for cytomegalovirus (CMV) but positive for <italic toggle="yes">H. pylori</italic>, for which the patient was initiated on quadruple therapy involving tetracycline, metronidazole, bismuth salicylate, and pantoprazole. A biopsy of the left-sided neck mass revealed lymphoid tissue with Reed-Sternberg cells and positive CD15 and CD30 markers, confirming classic Hodgkin’s lymphoma of the nodular sclerosis type. A bone marrow biopsy was negative for malignant involvement.</p><p>The patient continued to decline with worsening cholestatic liver injury and physical signs of hepatic dysfunction, including jaundiced skin and sclera, despite empiric treatment with ursodiol. No other causes of liver injury, such as viral hepatitis, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, or inherited conditions, were found on workup, including serologies and imaging. A liver biopsy was pursued, which showed bile duct injury accompanied by ductopenia affecting more than 50% of the portal tracts and severe macrovesicular steatosis without fibrosis, as seen in Figures <xref ref-type="fig" rid="FIG5">5</xref>-<xref ref-type="fig" rid="FIG6">6</xref>. No histologic evidence of direct lymphomatous invasion was found.</p><fig fig-type="figure" id="FIG5" orientation="portrait" position="anchor"><label>Figure 5</label><caption><title>Liver core biopsies demonstrating macrovesicular steatosis (A, periodic acid-Schiff stain with diastase, 40×) and marked canalicular-predominant cholestasis (B, arrow; periodic acid-Schiff stain with diastase, 400×)</title><p>Credit: Payman Fathizadeh, MD</p></caption><graphic orientation="portrait" position="float" xlink:href="cureus-0018-00000100708-i05.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><fig fig-type="figure" id="FIG6" orientation="portrait" position="anchor"><label>Figure 6</label><caption><title>Liver core biopsies demonstrate canalicular cholestasis (A, hematoxylin and eosin stain, 400x), approximately 70% macrovesicular steatosis (B, hematoxylin and eosin stain, 100x), and significant bile duct loss (C, hematoxylin and eosin stain, 400x)</title><p>The few remaining bile ducts exhibit evidence of injury and degenerative changes. These histologic findings are consistent with ductopenia/vanishing bile duct syndrome, which may be associated with drug-induced liver injury or the patient's documented history of Hodgkin lymphoma. The concurrent macrovesicular steatosis may also represent a manifestation of drug-related hepatotoxicity. No evidence of lymphomatous infiltration is identified. The histologic features do not suggest extrahepatic biliary obstruction.</p><p>Credit: Payman Fathizadeh, MD</p></caption><graphic orientation="portrait" position="float" xlink:href="cureus-0018-00000100708-i06.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><p>The patient denied any use of herbal remedies, over-the-counter drugs, or other culprit medication use that implicated concern for drug-induced liver injury. Given the absence of other identifiable etiologies, the findings of cholestatic liver injury and severe ductopenia on liver biopsy were thought to most likely represent VBDS as a paraneoplastic phenomenon in the setting of newly diagnosed Hodgkin's lymphoma (HL). At this juncture, given extremely poor liver function and dependence on hepatic metabolism for the use of most active agents in the treatment of cHL, we had an extensive discussion with the patient and his family. We shared that not treating the disease would likely result in fulminant liver failure. However, treatment of the disease with optimal therapy would likely result in severe treatment-related toxicities, amplifying known cytopenias, emetogenesis, cardiotoxicities, and more. The option of hospice was introduced to the patient, given worsening liver function tests, and he opted to continue with full care, given that he is the sole provider for his two children.</p><p>The patient was initiated on chemotherapy with cyclophosphamide, brentuximab vedotin, and dexamethasone. He received one cycle of inpatient and was discharged with ursodiol. Liver function improved with one dose of therapy, and treatment was accordingly continued with additional cHL-specific treatments, including brentuximab vedotin, vinblastine, and dacarbazine. These drugs were chosen due to their known efficacy and ability to modify the doses in the setting of impaired liver function. Doxorubicin and bleomycin were omitted due to the risk of severe toxicities, which could further augment mortality risk. At the time of writing this article, our patient has completed four cycles of chemotherapy with a peak in liver function tests around cycle 2 and subsequent downtrending with additional cycles of chemotherapy. Interval imaging with CT of his neck showed a marked decrease in the size of his left neck lymphadenopathy, as seen in Figure <xref ref-type="fig" rid="FIG7">7</xref>.</p><fig fig-type="figure" id="FIG7" orientation="portrait" position="anchor"><label>Figure 7</label><caption><title>Interval imaging of the CT neck showing marked decrease in the size and number of left jugulodigastric chain adenopathy as labeled by the red arrow, largest measuring 13 mm x 24 mm x 38 mm</title></caption><graphic orientation="portrait" position="float" xlink:href="cureus-0018-00000100708-i07.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><p>Figure <xref ref-type="fig" rid="FIG8">8</xref> demonstrates the overall trend for the patient’s liver tests throughout his presentation.</p><fig fig-type="figure" id="FIG8" orientation="portrait" position="anchor"><label>Figure 8</label><caption><title>Trend of alkaline phosphatase, AST, ALT, and bilirubin throughout the patient’s presentation</title><p>Cycle indicates when the patient received chemotherapy. Cycle 1: brentuximab, cyclophosphamide, dexamethasone; Cycle 2: cyclophosphamide, dexamethasone; Cycle 3 and Cycle 4: brentuximab, vinblastine, dacarbazine</p><p>ALT: alanine transaminase; AST: aspartate aminotransferase</p></caption><graphic orientation="portrait" position="float" xlink:href="cureus-0018-00000100708-i08.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><p>The patient was not considered an orthotopic liver transplant candidate, given his active lymphoma and lack of adequate family or social support for post-transplant care. Transplant assessment remains on hold pending completion of Hodgkin's lymphoma treatment, and issues related to care planning, such as securing appropriate caregiver support, are resolved.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>The association between VBDS and HL was first described in 1993 by Hubscher et al. [<xref ref-type="bibr" rid="REF3">3</xref>] and, since then, has been described in a number of published cases. We compiled a list of all published case reports through a search of the PubMed database, Science Direct, and Google Scholar, including both English and non-English cases, which is summarized in Table <xref ref-type="table" rid="TAB2">2</xref>.</p><table-wrap id="TAB2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Case report search of VBDS spanning from 1962 to 2025 with descriptions of liver biopsy findings, HL treatment received, and patient outcomes</title><p>Source: [<xref ref-type="bibr" rid="REF4">4</xref>-<xref ref-type="bibr" rid="REF48">48</xref>]</p><p>HL: Hodgkin’s lymphoma; VBDS: Vanishing bile duct syndrome; IC: Idiopathic cholestasis</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Author</td><td colspan="1" rowspan="1">Year</td><td colspan="1" rowspan="1">Liver biopsy</td><td colspan="1" rowspan="1">HL treatment (chemotherapy and/or radiation)</td><td colspan="1" rowspan="1">Outcome/cause of death</td></tr><tr><td colspan="1" rowspan="1">Hasan F [<xref ref-type="bibr" rid="REF4">4</xref>]</td><td colspan="1" rowspan="1">2024</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Unknown</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Patodiya B [<xref ref-type="bibr" rid="REF5">5</xref>]</td><td colspan="1" rowspan="1">2023</td><td colspan="1" rowspan="1">Lobular inflammation</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr><td colspan="1" rowspan="1">Nano O [<xref ref-type="bibr" rid="REF6">6</xref>]</td><td colspan="1" rowspan="1">2023</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Shokri F [<xref ref-type="bibr" rid="REF7">7</xref>]</td><td colspan="1" rowspan="1">2023</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/hepatic and renal failure</td></tr><tr><td colspan="1" rowspan="1">Keramidas V [<xref ref-type="bibr" rid="REF8">8</xref>]</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Papakonstantinou I [<xref ref-type="bibr" rid="REF9">9</xref>]</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">IC</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr><td colspan="1" rowspan="1">Ousley RJ [<xref ref-type="bibr" rid="REF10">10</xref>]</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Greca RD [<xref ref-type="bibr" rid="REF11">11</xref>]</td><td colspan="1" rowspan="1">2020</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Unknown</td></tr><tr><td colspan="1" rowspan="1">Bakhit M [<xref ref-type="bibr" rid="REF12">12</xref>]</td><td colspan="1" rowspan="1">2017</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Unknown</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Rota Scalabrini D [<xref ref-type="bibr" rid="REF13">13</xref>]</td><td colspan="1" rowspan="1">2014</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr><td colspan="1" rowspan="1">Nader K [<xref ref-type="bibr" rid="REF14">14</xref>]</td><td colspan="1" rowspan="1">2013</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/hepatic failure and sepsis</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Aleem A [<xref ref-type="bibr" rid="REF15">15</xref>]</td><td colspan="1" rowspan="1">2013</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/hepatic failure</td></tr><tr><td colspan="1" rowspan="1">Wong KM [<xref ref-type="bibr" rid="REF16">16</xref>]</td><td colspan="1" rowspan="1">2013</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Umit H [<xref ref-type="bibr" rid="REF17">17</xref>]</td><td colspan="1" rowspan="1">2009</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Unknown</td><td colspan="1" rowspan="1">Unknown</td></tr><tr><td colspan="1" rowspan="1">Pass AK [<xref ref-type="bibr" rid="REF18">18</xref>]</td><td colspan="1" rowspan="1">2008</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission/awaiting liver transplant</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Pass AK [<xref ref-type="bibr" rid="REF18">18</xref>]</td><td colspan="1" rowspan="1">2008</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/aspiration</td></tr><tr><td colspan="1" rowspan="1">Leeuwenburgh I [<xref ref-type="bibr" rid="REF19">19</xref>]</td><td colspan="1" rowspan="1">2008</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">DeBenedet AT [<xref ref-type="bibr" rid="REF20">20</xref>]</td><td colspan="1" rowspan="1">2008</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/unknown</td></tr><tr><td colspan="1" rowspan="1">Ballonoff A [<xref ref-type="bibr" rid="REF21">21</xref>]</td><td colspan="1" rowspan="1">2007</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Barta SK [<xref ref-type="bibr" rid="REF22">22</xref>]</td><td colspan="1" rowspan="1">2006</td><td colspan="1" rowspan="1">IC</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr><td colspan="1" rowspan="1">Schmitt A [<xref ref-type="bibr" rid="REF23">23</xref>]</td><td colspan="1" rowspan="1">2006</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Death/sepsis</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Han WS [<xref ref-type="bibr" rid="REF24">24</xref>]</td><td colspan="1" rowspan="1">2005</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Unknown</td><td colspan="1" rowspan="1">Recurrent HL</td></tr><tr><td colspan="1" rowspan="1">Cordoba Iturriagagaitia A [<xref ref-type="bibr" rid="REF25">25</xref>]</td><td colspan="1" rowspan="1">2005</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Unknown</td><td colspan="1" rowspan="1">Remission</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Guliter S [<xref ref-type="bibr" rid="REF26">26</xref>]</td><td colspan="1" rowspan="1">2004</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/sepsis</td></tr><tr><td colspan="1" rowspan="1">Liangpunsakul S [<xref ref-type="bibr" rid="REF27">27</xref>]</td><td colspan="1" rowspan="1">2002</td><td colspan="1" rowspan="1">Cholestatic hepatitis</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Komurcu S [<xref ref-type="bibr" rid="REF28">28</xref>]</td><td colspan="1" rowspan="1">2002</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/hepatic failure</td></tr><tr><td colspan="1" rowspan="1">Ripoll C [<xref ref-type="bibr" rid="REF29">29</xref>]</td><td colspan="1" rowspan="1">2002</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/hepatic failure</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Ripoll C [<xref ref-type="bibr" rid="REF29">29</xref>]</td><td colspan="1" rowspan="1">2002</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr><td colspan="1" rowspan="1">Ozkan A [<xref ref-type="bibr" rid="REF30">30</xref>]</td><td colspan="1" rowspan="1">2001</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/hepatic failure</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Allory Y [<xref ref-type="bibr" rid="REF31">31</xref>]</td><td colspan="1" rowspan="1">2000</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Unknown</td><td colspan="1" rowspan="1">Unknown</td></tr><tr><td colspan="1" rowspan="1">Rossini MS [<xref ref-type="bibr" rid="REF32">32</xref>]</td><td colspan="1" rowspan="1">2000</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/hepatic failure</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Yusuf MA [<xref ref-type="bibr" rid="REF33">33</xref>]</td><td colspan="1" rowspan="1">2000</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/hepatic failure</td></tr><tr><td colspan="1" rowspan="1">Dourakis SP [<xref ref-type="bibr" rid="REF34">34</xref>]</td><td colspan="1" rowspan="1">1999</td><td colspan="1" rowspan="1">Hepatocellular necrosis</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/hepatic failure</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Yalcin S [<xref ref-type="bibr" rid="REF35">35</xref>]</td><td colspan="1" rowspan="1">1999</td><td colspan="1" rowspan="1">IC</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Death/sepsis</td></tr><tr><td colspan="1" rowspan="1">Yalcin S [<xref ref-type="bibr" rid="REF35">35</xref>]</td><td colspan="1" rowspan="1">1999</td><td colspan="1" rowspan="1">IC</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">De Medeiros BC [<xref ref-type="bibr" rid="REF36">36</xref>]</td><td colspan="1" rowspan="1">1998</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/hepatic failure</td></tr><tr><td colspan="1" rowspan="1">De Medeiros BC [<xref ref-type="bibr" rid="REF36">36</xref>]</td><td colspan="1" rowspan="1">1998</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Crosbie OM [<xref ref-type="bibr" rid="REF37">37</xref>]</td><td colspan="1" rowspan="1">1997</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr><td colspan="1" rowspan="1">Gottrand F [<xref ref-type="bibr" rid="REF38">38</xref>]</td><td colspan="1" rowspan="1">1997</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Death/hepatic failure</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Warner AS [<xref ref-type="bibr" rid="REF39">39</xref>]</td><td colspan="1" rowspan="1">1994</td><td colspan="1" rowspan="1">IC</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr><td colspan="1" rowspan="1">Jansen PLM [<xref ref-type="bibr" rid="REF40">40</xref>]</td><td colspan="1" rowspan="1">1994</td><td colspan="1" rowspan="1">IC</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/variceal hemorrhage</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Hubscher SG [<xref ref-type="bibr" rid="REF3">3</xref>]</td><td colspan="1" rowspan="1">1993</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/pneumonia</td></tr><tr><td colspan="1" rowspan="1">Hubscher SG [<xref ref-type="bibr" rid="REF3">3</xref>]</td><td colspan="1" rowspan="1">1993</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/unknown</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Hubscher SG [<xref ref-type="bibr" rid="REF3">3</xref>]</td><td colspan="1" rowspan="1">1993</td><td colspan="1" rowspan="1">VBDS</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/sepsis</td></tr><tr><td colspan="1" rowspan="1">Birrer MJ [<xref ref-type="bibr" rid="REF41">41</xref>]</td><td colspan="1" rowspan="1">1987</td><td colspan="1" rowspan="1">IC</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/sepsis</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Lieberman DA [<xref ref-type="bibr" rid="REF42">42</xref>]</td><td colspan="1" rowspan="1">1986</td><td colspan="1" rowspan="1">IC</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Death/respiratory arrest</td></tr><tr><td colspan="1" rowspan="1">Trewby PN [<xref ref-type="bibr" rid="REF43">43</xref>]</td><td colspan="1" rowspan="1">1979</td><td colspan="1" rowspan="1">IC</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Trewby PN [<xref ref-type="bibr" rid="REF43">43</xref>]</td><td colspan="1" rowspan="1">1979</td><td colspan="1" rowspan="1">Mild portal hepatitis</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Death</td></tr><tr><td colspan="1" rowspan="1">Trewby PN [<xref ref-type="bibr" rid="REF43">43</xref>]</td><td colspan="1" rowspan="1">1979</td><td colspan="1" rowspan="1">Lymphoma infiltration</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Trewby PN [<xref ref-type="bibr" rid="REF43">43</xref>]</td><td colspan="1" rowspan="1">1979</td><td colspan="1" rowspan="1">Lymphoma infiltration</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Death</td></tr><tr><td colspan="1" rowspan="1">Trewby PN [<xref ref-type="bibr" rid="REF43">43</xref>]</td><td colspan="1" rowspan="1">1979</td><td colspan="1" rowspan="1">Mixed inflammatory and atypical histiocytes</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Trewby PN [<xref ref-type="bibr" rid="REF43">43</xref>]</td><td colspan="1" rowspan="1">1979</td><td colspan="1" rowspan="1">IC</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/hepatic failure</td></tr><tr><td colspan="1" rowspan="1">Piken EP [<xref ref-type="bibr" rid="REF44">44</xref>]</td><td colspan="1" rowspan="1">1979</td><td colspan="1" rowspan="1">IC</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/unknown</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Perera DR [<xref ref-type="bibr" rid="REF45">45</xref>]</td><td colspan="1" rowspan="1">1974</td><td colspan="1" rowspan="1">IC</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/hepatic failure</td></tr><tr><td colspan="1" rowspan="1">Perera DR [<xref ref-type="bibr" rid="REF45">45</xref>]</td><td colspan="1" rowspan="1">1974</td><td colspan="1" rowspan="1">IC</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Perera DR [<xref ref-type="bibr" rid="REF45">45</xref>]</td><td colspan="1" rowspan="1">1974</td><td colspan="1" rowspan="1">IC</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Remission</td></tr><tr><td colspan="1" rowspan="1">Groth C [<xref ref-type="bibr" rid="REF46">46</xref>]</td><td colspan="1" rowspan="1">1972</td><td colspan="1" rowspan="1">IC</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/hepatic failure</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Juniper K [<xref ref-type="bibr" rid="REF47">47</xref>]</td><td colspan="1" rowspan="1">1963</td><td colspan="1" rowspan="1">IC</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/hepatic failure</td></tr><tr><td colspan="1" rowspan="1">Bouroncle B [<xref ref-type="bibr" rid="REF48">48</xref>]</td><td colspan="1" rowspan="1">1962</td><td colspan="1" rowspan="1">IC</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/hepatic failure</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Bouroncle B [<xref ref-type="bibr" rid="REF48">48</xref>]</td><td colspan="1" rowspan="1">1962</td><td colspan="1" rowspan="1">IC</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Death/hepatic failure</td></tr></tbody></table></table-wrap><p>Among the 60 case reports listed above, remission was achieved in 36.67% of cases (n=22), not including those patients whose outcomes were unknown. Although liver function test abnormalities and hepatic involvement with HL can be seen in up to 50% of patients due to hemolysis, biliary obstruction from lymph node enlargement, and viral illness such as CMV, VBDS specifically is a rare manifestation of HL patients and overall can be a marker of poor prognosis [<xref ref-type="bibr" rid="REF12">12</xref>]. Differentiating VBDS from HL involvement of the liver relies on liver biopsy showing histologic evidence of more than 50% interlobular bile duct loss in a specimen that includes at least 10 portal tracts [<xref ref-type="bibr" rid="REF1">1</xref>]. In severe instances, a biopsy may show a total lack of bile ducts with complete ductopenia, having "burnt-out" portal tracts that are devoid of bile ducts [<xref ref-type="bibr" rid="REF1">1</xref>]. Diagnosing VBDS can therefore be difficult due to its nonspecific symptoms and the necessity of a liver biopsy to confirm the absence of bile ducts.</p><p>The pathophysiology is complex and postulated to be multifactorial, involving autoimmune, inflammatory, and regenerative factors all playing a role in the destruction of bile ducts, though the precise mechanism is unclear [<xref ref-type="bibr" rid="REF1">1</xref>]. The onset of VBDS is believed to be linked to the heightened apoptosis of biliary epithelial cells, which occurs in response to triggers such as death receptor activation, autoimmune disease, ischemia, oxidative stress, toxins, and viral pathogens. Some theories include cell-mediated immunologic reactions leading to ductopenia, auto-apoptosis of biliary epithelium, or cytokines released by lymphoma cells [<xref ref-type="bibr" rid="REF1">1</xref>].</p><p>VBDS can occur as both an irreversible and a transient condition. While some cases progress to fibrosis, cirrhosis, and liver failure, others may improve over months to years. Liver transplantation is reserved for advanced or refractory cases when the condition leads to significant ductopenia, biliary cirrhosis, and liver failure. However, it is important to consider treatment of the underlying cause and the possibility of biliary regeneration [<xref ref-type="bibr" rid="REF49">49</xref>-<xref ref-type="bibr" rid="REF52">52</xref>]. Broadly speaking, VBDS of any origin can be considered for treatment with corticosteroids and ursodeoxycholic acid (UDCA) that may slow inflammation and stimulate bile secretion, preventing apoptosis of cholangiocytes. UDCA utilizes multiple strategies to defend cholangiocytes from the damaging impact of bile acids and to boost the function of impaired hepatobiliary secretion [<xref ref-type="bibr" rid="REF53">53</xref>-<xref ref-type="bibr" rid="REF55">55</xref>].</p><p>From an oncology perspective, treatment of HL-related VBDS is controversial due to the selection of agents, timing of initiation, and questions regarding liver transplantation referral and candidacy. It overall makes treating an otherwise curable malignancy quite challenging. This is because the standard-of-care treatment for HL is with the first-line regimen known as ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine. However, doxorubicin and vinblastine are both hepatically metabolized. Doxorubicin is contraindicated if bilirubin is higher than 5.0 mg/dL, and vinblastine is contraindicated if the AST/ALT are greater than three times the upper limit of normal. There is no consensus on first-line therapy in this setting. Whether the modified ABVD regimen should be given with dose adjustment, or if the second-line regimen GDP (gemcitabine 1,600 mg (1,000 mg/m<sup>2</sup> IV infusion), dexamethasone 40 mg (once daily orally), and carboplatin 600 mg infusion (target AUC of 4-6 mg/mL/min)) should be used is unclear and provider-dependent [<xref ref-type="bibr" rid="REF13">13</xref>]. Scalabrini et al. reported that only 12% of patients with VBDS who received an upfront reduced ABVD regimen had improved cholestasis and liver function impairment compared to 51% of patients receiving the full dose [<xref ref-type="bibr" rid="REF13">13</xref>] and therefore advocate for normal dosing. However, it is important to note that these specific patients initially responded well clinically to high doses of UDCA and prednisone prior to receiving ABVD. Conventionally, most other clinicians will attempt modified or alternative regimens to treat the underlying HL until the hyperbilirubinemia normalizes enough to allow ABVD treatment, such as single-agent chemotherapy that is not hepatically metabolized or dose-reduction [<xref ref-type="bibr" rid="REF6">6</xref>]. Literature review also shows favorable outcomes with the use of nivolumab (a programmed cell death protein or PD-1 receptor inhibitor that prevents T-cell silencing) and brentuximab (an antibody-drug conjugate that binds to cluster of differentiation or CD-30 antigen on cancer cells that disrupts microtubules and leads to cell apoptosis) [<xref ref-type="bibr" rid="REF5">5</xref>,<xref ref-type="bibr" rid="REF11">11</xref>,<xref ref-type="bibr" rid="REF56">56</xref>]. For example, Gupta et al. reported a favorable outcome in patients first given single-agent brentuximab as bridging therapy [<xref ref-type="bibr" rid="REF57">57</xref>]. Liver transplant was discussed in some of the reviewed case reports as last-line therapy for irreversible cirrhosis; however, active HL disease often precludes these patients from being on the transplant list.</p><p>Regarding our patient, he was started on chemotherapy with cyclophosphamide, dexamethasone, and brentuximab vedotin, a combination therapy modified to minimize hepatotoxicity [<xref ref-type="bibr" rid="REF58">58</xref>] and the potential toxicities of impaired hepatic drug clearance. His labs showed stable liver tests after the first cycle of treatment. Though his liver tests continued to rise thereafter, at the time of writing this article, the patient has completed four cycles of treatment, and his liver tests are improving. He was evaluated by the liver transplant team at a nearby hospital, and a multidisciplinary decision was made to defer transplant until the cHL is completely treated. We posit that liver transplantation should be considered in cHL patients who achieve complete remission after systemic therapy, given the irreversible nature of bile duct loss.</p><p>Generally, active malignancy other than within the confines of specific exceptions for liver transplant (e.g., hepatocellular carcinoma, perihepatic cholangiocarcinoma, other emerging indications) precludes consideration for liver transplant for a two- to five-year period following treatment at many centers. Liver transplantation for VBDS in cHL is controversial and likely rare. To our knowledge, this may be one of the first cases in which an orthotopic liver transplant was being considered as treatment for VBDS in an active cHL patient. While these decisions are complex and need to be made in a multidisciplinary setting with the transplant team and oncology, taking into account potential benefits, risks of relapse/recurrence, and post-transplant immunosuppressive risks, we posit that liver transplantation may be a potential consideration in select cHL patients with VBDS that are not improving who achieve complete remission after systemic therapy given the irreversible nature of bile duct loss.</p><p>Although VBDS often portends a poor prognosis in HL patients due to the irreversible nature of bile duct loss leading to hepatic failure and death, recent case reports suggest a possibility of reversal or at least improved survival among patients who respond to cancer treatment. This ranges from complete remission with treatment of lymphoma with either total resolution in lab abnormalities or lingering mild isolated elevation in alkaline phosphatase levels without clinical symptoms [<xref ref-type="bibr" rid="REF12">12</xref>].</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>VBDS is a rare paraneoplastic phenomenon of cHL whose pathophysiology is incompletely understood but thought to be related to lymphoma cytokine release or cell-mediated immunologic reactions causing ductopenia. Rarely, it can be reversible with treatment of cHL, but otherwise can progress to acute liver failure with high mortality rates. It is important to recognize VBDS related to cHL early to initiate treatment with careful consideration of the limiting factors and the potential need for early liver transplant evaluation, if clinically indicated. It is important to acknowledge that, while liver transplantation may be a potential consideration if the liver injury fails to improve in those achieving complete remission, the role of liver transplant in this setting remains limited, is controversial, and needs to be determined in a multidisciplinary transplant setting. Further steps include standardizing the treatment of cHL-related VBDS to optimize survival outcomes.</p></sec></body><back><fn-group content-type="conflict"><title>Disclosures</title><fn fn-type="COI-statement"><p><bold>Human subjects:</bold> Informed consent for treatment and open access publication was obtained or waived by all participants in this study.</p><p><bold>Conflicts of interest:</bold> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p><p><bold>Payment/services info:</bold> All authors have declared that no financial support was received from any organization for the submitted work.</p><p><bold>Financial relationships:</bold> Shaun Chandna, DO declare(s) a grant from Arrowhead Pharmaceuticals. Shaun Chandna, DO declare(s) a grant from Lipocine. Shaun Chandna, DO declare(s) a grant from Mirum Pharmaceuticals. Shaun Chandna, DO declare(s) a grant from Calliditas Therapeutics (formerly Genkyotex). Shaun Chandna, DO declare(s) personal fees from Ipsen. Consulting. Shaun Chandna, DO declare(s) personal fees from Mirum Pharmaceuticals. Consulting. Shaun Chandna, DO declare(s) personal fees from Madrigal Pharmaceuticals. Speaker bureau and consulting.</p><p><bold>Other relationships:</bold> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p></fn></fn-group><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>  Jody W. Tai, Jessica Yan, Vivek D. Shah, Phyllis Kim, Rhett L. Harmon, Shaun Chandna, Deepthi Karunasiri</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>  Jody W. Tai, Jessica Yan, Vivek D. Shah, Phyllis Kim, Shaun Chandna, Simon Beaven, Deepthi Karunasiri, Payman Fathizadeh</p><p><bold>Drafting of the manuscript:</bold>  Jody W. Tai, Jessica Yan, Vivek D. Shah, Phyllis Kim, Rhett L. Harmon, Shaun Chandna</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>  Jody W. Tai, Jessica Yan, Vivek D. Shah, Phyllis Kim, Shaun Chandna, Simon Beaven, Deepthi Karunasiri, Payman Fathizadeh</p><p><bold>Supervision:</bold>  Jessica Yan, Phyllis Kim, Shaun Chandna</p></fn></fn-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="book"><article-title>Vanishing bile duct syndrome</article-title><source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</source><person-group>
<name name-style="western"><surname>National Institute of Diabetes and Digestive and Kidney</surname><given-names>Diseases</given-names></name>
</person-group><publisher-loc>Bethesda, MD</publisher-loc><publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name><year>2019</year><uri xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK548715/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.ncbi.nlm.nih.gov/books/NBK548715/</uri><pub-id pub-id-type="pmid">31643176</pub-id></element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>International prognostic score in advanced-stage Hodgkin’s lymphoma: altered utility in the modern era</article-title><source>J Clin Oncol</source><person-group>
<name name-style="western"><surname>Moccia</surname><given-names>AA</given-names></name>
<name name-style="western"><surname>Donaldson</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Chhanabhai</surname><given-names>M</given-names></name>
<etal/>
</person-group><fpage>3383</fpage><lpage>3388</lpage><volume>30</volume><year>2012</year><pub-id pub-id-type="pmid">22869887</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1200/JCO.2011.41.0910</pub-id></element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma</article-title><source>Hepatology</source><person-group>
<name name-style="western"><surname>Hubscher</surname><given-names>SG</given-names></name>
<name name-style="western"><surname>Lumley</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Elias</surname><given-names>E</given-names></name>
</person-group><fpage>70</fpage><lpage>77</lpage><volume>17</volume><year>1993</year><uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/7678577/" xmlns:xlink="http://www.w3.org/1999/xlink">https://pubmed.ncbi.nlm.nih.gov/7678577/</uri><pub-id pub-id-type="pmid">7678577</pub-id></element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Vanishing bile duct syndrome in advanced Hodgkin’s lymphoma: a case report of diagnostic and therapeutic challenges</article-title><source>Am J Gastroenterol</source><person-group>
<name name-style="western"><surname>Hasan</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Garcia</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Singh</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Timsaal</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Alabd</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Shah</surname><given-names>A</given-names></name>
</person-group><fpage>0</fpage><lpage>20</lpage><volume>119</volume><year>2024</year></element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>A rare presentation of vanishing bile duct syndrome in Hodgkin lymphoma: case report</article-title><source>SAGE Open Med Case Rep</source><person-group>
<name name-style="western"><surname>Patodiya</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Ramani</surname><given-names>VK</given-names></name>
<name name-style="western"><surname>Rao</surname><given-names>PN</given-names></name>
<name name-style="western"><surname>Sharma</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Patodiya</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Reddy</surname><given-names>DN</given-names></name>
</person-group><fpage>2050313</fpage><volume>11</volume><year>2023</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.1177/2050313X231208968</pub-id><pub-id pub-id-type="pmcid">PMC10637155</pub-id><pub-id pub-id-type="pmid">37954540</pub-id></element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Vanishing bile duct syndrome in a patient with recurrent Hodgkin lymphoma</article-title><source>J Med Cases</source><person-group>
<name name-style="western"><surname>Nano</surname><given-names>O</given-names></name>
<name name-style="western"><surname>Ivanov</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Kapoor</surname><given-names>T</given-names></name>
</person-group><fpage>162</fpage><lpage>168</lpage><volume>14</volume><year>2023</year><pub-id pub-id-type="pmid">37303969</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.14740/jmc4073</pub-id><pub-id pub-id-type="pmcid">PMC10251707</pub-id></element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Fatal vanishing bile duct syndrome in Iranian patient with Hodgkin's lymphoma</article-title><source>Clin Case Rep</source><person-group>
<name name-style="western"><surname>Shokri</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Shariati</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Veisari</surname><given-names>AK</given-names></name>
<etal/>
</person-group><fpage>0</fpage><volume>11</volume><year>2023</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/ccr3.7671</pub-id><pub-id pub-id-type="pmcid">PMC10357002</pub-id><pub-id pub-id-type="pmid">37484745</pub-id></element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Vanishing bile duct syndrome and Hodgkin’s lymphoma: case report and thorough review of the literature</article-title><source>Ann Hematol Oncol</source><person-group>
<name name-style="western"><surname>Keramidas</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Tastanis</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Tsirogianni</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Hytiroglou</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Papaioannou</surname><given-names>M</given-names></name>
</person-group><fpage>1365</fpage><volume>8</volume><year>2021</year><uri xlink:href="https://austinpublishinggroup.com/hematology/fulltext/hematology-v8-id1365.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">https://austinpublishinggroup.com/hematology/fulltext/hematology-v8-id1365.pdf</uri></element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>Paraneoplastic intrahepatic cholestasis in supradiaphragmatic classical Hodgkin lymphoma successfully treated with brentuximab vedotin: a case report and review of the literature</article-title><source>In Vivo</source><person-group>
<name name-style="western"><surname>Papakonstantinou</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Kosmidou</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Papathanasiou</surname><given-names>K</given-names></name>
<etal/>
</person-group><fpage>1951</fpage><lpage>1957</lpage><volume>35</volume><year>2021</year><pub-id pub-id-type="pmid">34182468</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.21873/invivo.12462</pub-id><pub-id pub-id-type="pmcid">PMC8286474</pub-id></element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>Now you see them, now you don’t: a rare case of vanishing bile duct syndrome</article-title><source>Am J Gastroenterol</source><person-group>
<name name-style="western"><surname>Ousley</surname><given-names>RJ</given-names></name>
<name name-style="western"><surname>Memon</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Al Diffalha</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Patel</surname><given-names>CR</given-names></name>
<name name-style="western"><surname>Gray</surname><given-names>M</given-names></name>
</person-group><fpage>0</fpage><lpage>10</lpage><volume>116</volume><year>2021</year></element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Vanishing bile duct syndrome related to DILI and Hodgkin lymphoma overlap: a rare and severe case</article-title><source>Ann Hepatol</source><person-group>
<name name-style="western"><surname>Greca</surname><given-names>RD</given-names></name>
<name name-style="western"><surname>Cunha-Silva</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Costa</surname><given-names>LB</given-names></name>
<etal/>
</person-group><fpage>107</fpage><lpage>112</lpage><volume>19</volume><year>2020</year><pub-id pub-id-type="pmid">31537508</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.aohep.2019.06.010</pub-id></element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>Vanishing bile duct syndrome in Hodgkin's lymphoma: a case report and literature review</article-title><source>World J Gastroenterol</source><person-group>
<name name-style="western"><surname>Bakhit</surname><given-names>M</given-names></name>
<name name-style="western"><surname>McCarty</surname><given-names>TR</given-names></name>
<name name-style="western"><surname>Park</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Njei</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Cho</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Karagozian</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Liapakis</surname><given-names>A</given-names></name>
</person-group><fpage>366</fpage><lpage>372</lpage><volume>23</volume><year>2017</year><pub-id pub-id-type="pmid">28127210</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.3748/wjg.v23.i2.366</pub-id><pub-id pub-id-type="pmcid">PMC5236516</pub-id></element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin's lymphoma: a case report and review of the literature</article-title><source>BMC Res Notes</source><person-group>
<name name-style="western"><surname>Scalabrini</surname><given-names>DR</given-names></name>
<name name-style="western"><surname>Caravelli</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Schianca</surname><given-names>FC</given-names></name>
<etal/>
</person-group><fpage>529</fpage><volume>7</volume><year>2014</year><pub-id pub-id-type="pmid">25125318</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1186/1756-0500-7-529</pub-id><pub-id pub-id-type="pmcid">PMC4143581</pub-id></element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="journal"><article-title>Vanishing bile duct syndrome as a manifestation of Hodgkin's lymphoma: a case report and review of the literature</article-title><source>Tumori</source><person-group>
<name name-style="western"><surname>Nader</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Mok</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Kalra</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Harb</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Schwarting</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Ferber</surname><given-names>A</given-names></name>
</person-group><fpage>0</fpage><lpage>8</lpage><volume>99</volume><year>2013</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.1177/030089161309900426</pub-id><pub-id pub-id-type="pmid">24326854</pub-id></element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>Vanishing bile duct syndrome in a Hodgkin's lymphoma patient with fatal outcome despite lymphoma remission</article-title><source>Saudi J Gastroenterol</source><person-group>
<name name-style="western"><surname>Aleem</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Al-Katari</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Alsaleh</surname><given-names>K</given-names></name>
<name name-style="western"><surname>AlSwat</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Al-Sheikh</surname><given-names>A</given-names></name>
</person-group><fpage>286</fpage><lpage>289</lpage><volume>19</volume><year>2013</year><pub-id pub-id-type="pmid">24195983</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.4103/1319-3767.121037</pub-id><pub-id pub-id-type="pmcid">PMC3958977</pub-id></element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="journal"><article-title>Hodgkin's lymphoma-related vanishing bile duct syndrome: a case report and literature review</article-title><source>Kaohsiung J Med Sci</source><person-group>
<name name-style="western"><surname>Wong</surname><given-names>KM</given-names></name>
<name name-style="western"><surname>Chang</surname><given-names>CS</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>CC</given-names></name>
<name name-style="western"><surname>Yin</surname><given-names>HL</given-names></name>
</person-group><fpage>636</fpage><lpage>641</lpage><volume>29</volume><year>2013</year><pub-id pub-id-type="pmid">24183359</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.kjms.2013.05.002</pub-id><pub-id pub-id-type="pmcid">PMC11916895</pub-id></element-citation></ref><ref id="REF17"><label>17</label><element-citation publication-type="journal"><article-title>Vanishing bile duct syndrome in a patient with Hodgkin's lymphoma and asymptomatic hepatitis B virus infection</article-title><source>Acta Gastroenterol Belg</source><person-group>
<name name-style="western"><surname>Umit</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Unsal</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Tezel</surname><given-names>A</given-names></name>
<etal/>
</person-group><fpage>277</fpage><lpage>278</lpage><volume>72</volume><year>2009</year><uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/19637792/" xmlns:xlink="http://www.w3.org/1999/xlink">https://pubmed.ncbi.nlm.nih.gov/19637792/</uri><pub-id pub-id-type="pmid">19637792</pub-id></element-citation></ref><ref id="REF18"><label>18</label><element-citation publication-type="journal"><article-title>Vanishing bile duct syndrome and Hodgkin disease: a case series and review of the literature</article-title><source>J Pediatr Hematol Oncol</source><person-group>
<name name-style="western"><surname>Pass</surname><given-names>AK</given-names></name>
<name name-style="western"><surname>McLin</surname><given-names>VA</given-names></name>
<name name-style="western"><surname>Rushton</surname><given-names>JR</given-names></name>
<name name-style="western"><surname>Kearney</surname><given-names>DL</given-names></name>
<name name-style="western"><surname>Hastings</surname><given-names>CA</given-names></name>
<name name-style="western"><surname>Margolin</surname><given-names>JF</given-names></name>
</person-group><fpage>976</fpage><lpage>980</lpage><volume>30</volume><year>2008</year><pub-id pub-id-type="pmid">19131796</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/MPH.0b013e31818b37c4</pub-id></element-citation></ref><ref id="REF19"><label>19</label><element-citation publication-type="journal"><article-title>Severe jaundice, due to vanishing bile duct syndrome, as presenting symptom of Hodgkin's lymphoma, fully reversible after chemotherapy</article-title><source>Eur J Gastroenterol Hepatol</source><person-group>
<name name-style="western"><surname>Leeuwenburgh</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Lugtenburg</surname><given-names>EP</given-names></name>
<name name-style="western"><surname>van Buuren</surname><given-names>HR</given-names></name>
<name name-style="western"><surname>Zondervan</surname><given-names>PE</given-names></name>
<name name-style="western"><surname>de Man</surname><given-names>RA</given-names></name>
</person-group><fpage>145</fpage><lpage>147</lpage><volume>20</volume><year>2008</year><pub-id pub-id-type="pmid">18188038</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/MEG.0b013e3282b9e6c2</pub-id></element-citation></ref><ref id="REF20"><label>20</label><element-citation publication-type="journal"><article-title>A case of vanishing bile duct syndrome and IBD secondary to Hodgkin's lymphoma</article-title><source>Nat Clin Pract Gastroenterol Hepatol</source><person-group>
<name name-style="western"><surname>DeBenedet</surname><given-names>AT</given-names></name>
<name name-style="western"><surname>Berg</surname><given-names>CL</given-names></name>
<name name-style="western"><surname>Enfield</surname><given-names>KB</given-names></name>
<name name-style="western"><surname>Woodford</surname><given-names>RL</given-names></name>
<name name-style="western"><surname>Bennett</surname><given-names>AK</given-names></name>
<name name-style="western"><surname>Northup</surname><given-names>PG</given-names></name>
</person-group><fpage>49</fpage><lpage>53</lpage><volume>5</volume><year>2008</year><pub-id pub-id-type="pmid">18174907</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/ncpgasthep1001</pub-id></element-citation></ref><ref id="REF21"><label>21</label><element-citation publication-type="journal"><article-title>Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis: statistical analysis of all published cases and literature review</article-title><source>Acta Oncol</source><person-group>
<name name-style="western"><surname>Ballonoff</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Kavanagh</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Nash</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Drabkin</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Trotter</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Costa</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Rabinovitch</surname><given-names>R</given-names></name>
</person-group><fpage>962</fpage><lpage>970</lpage><volume>47</volume><year>2008</year><pub-id pub-id-type="pmid">17906981</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1080/02841860701644078</pub-id></element-citation></ref><ref id="REF22"><label>22</label><element-citation publication-type="journal"><article-title>Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin's lymphoma</article-title><source>Clin Lymphoma Myeloma</source><person-group>
<name name-style="western"><surname>Barta</surname><given-names>SK</given-names></name>
<name name-style="western"><surname>Yahalom</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Shia</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Hamlin</surname><given-names>PA</given-names></name>
</person-group><fpage>77</fpage><lpage>82</lpage><volume>7</volume><year>2006</year><pub-id pub-id-type="pmid">16879775</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.3816/CLM.2006.n.044</pub-id></element-citation></ref><ref id="REF23"><label>23</label><element-citation publication-type="journal"><article-title>Clinical problem-solving. Empirically incorrect</article-title><source>N Engl J Med</source><person-group>
<name name-style="western"><surname>Schmitt</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Gilden</surname><given-names>DJ</given-names></name>
<name name-style="western"><surname>Saint</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Moseley</surname><given-names>RH</given-names></name>
</person-group><fpage>509</fpage><lpage>514</lpage><volume>354</volume><year>2006</year><pub-id pub-id-type="pmid">16452563</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1056/NEJMcps051762</pub-id></element-citation></ref><ref id="REF24"><label>24</label><element-citation publication-type="journal"><article-title>[Spontaneous resolution of vanishing bile duct syndrome in Hodgkin's lymphoma]</article-title><source>Korean J Hepatol</source><person-group>
<name name-style="western"><surname>Han</surname><given-names>WS</given-names></name>
<name name-style="western"><surname>Jung</surname><given-names>ES</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>YH</given-names></name>
<etal/>
</person-group><fpage>164</fpage><lpage>168</lpage><volume>11</volume><year>2005</year><uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/15980675/" xmlns:xlink="http://www.w3.org/1999/xlink">https://pubmed.ncbi.nlm.nih.gov/15980675/</uri><pub-id pub-id-type="pmid">15980675</pub-id></element-citation></ref><ref id="REF25"><label>25</label><element-citation publication-type="journal"><article-title>[Ductal regeneration in vanishing bile duct syndrome in Hodgkin's lymphoma]</article-title><source>Gastroenterol Hepatol</source><person-group>
<name name-style="western"><surname>Córdoba Iturriagagoitia</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Iñarrairaegui Bastarrica</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Pérez de Equiza</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Zozaya Urmeneta</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Martínez-Peñuela</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Beloqui Pérez</surname><given-names>R</given-names></name>
</person-group><fpage>275</fpage><lpage>278</lpage><volume>28</volume><year>2005</year><pub-id pub-id-type="pmid">15871809</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1157/13074061</pub-id></element-citation></ref><ref id="REF26"><label>26</label><element-citation publication-type="journal"><article-title>Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) in Hodgkin's disease: report of a case</article-title><source>Tumori</source><person-group>
<name name-style="western"><surname>Guliter</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Erdem</surname><given-names>O</given-names></name>
<name name-style="western"><surname>Isik</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Yamac</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Uluoglu</surname><given-names>O</given-names></name>
</person-group><fpage>517</fpage><lpage>520</lpage><volume>90</volume><year>2004</year><pub-id pub-id-type="pmid">15656342</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1177/030089160409000516</pub-id></element-citation></ref><ref id="REF27"><label>27</label><element-citation publication-type="journal"><article-title>Hodgkin's disease presenting as cholestatic hepatitis with prominent ductal injury</article-title><source>Eur J Gastroenterol Hepatol</source><person-group>
<name name-style="western"><surname>Liangpunsakul</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Kwo</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Koukoulis</surname><given-names>GK</given-names></name>
</person-group><fpage>323</fpage><lpage>327</lpage><volume>14</volume><year>2002</year><pub-id pub-id-type="pmid">11953700</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/00042737-200203000-00019</pub-id></element-citation></ref><ref id="REF28"><label>28</label><element-citation publication-type="journal"><article-title>Vanishing bile duct syndrome occurring after high-dose chemotherapy and autologous peripheral stem cell transplantation in a patient with Hodgkin's disease</article-title><source>Ann Hematol</source><person-group>
<name name-style="western"><surname>Kömürcü</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Ozet</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Altundag</surname><given-names>MK</given-names></name>
<name name-style="western"><surname>Arpaci</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Oztürk</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Celasun</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Tezcan</surname><given-names>Y</given-names></name>
</person-group><fpage>57</fpage><lpage>58</lpage><volume>81</volume><year>2002</year><pub-id pub-id-type="pmid">11807639</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s00277-001-0406-7</pub-id></element-citation></ref><ref id="REF29"><label>29</label><element-citation publication-type="journal"><article-title>[Idiopathic cholestasis associated with progressive ductopenia in two patients with Hodgkin's disease]</article-title><source>Gastroenterol Hepatol</source><person-group>
<name name-style="western"><surname>Ripoll</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Carretero</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Sabin</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Alvarez</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Marrupe</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Bañares</surname><given-names>R</given-names></name>
</person-group><fpage>313</fpage><lpage>315</lpage><volume>25</volume><year>2002</year><pub-id pub-id-type="pmid">11985802</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/s0210-5705(02)79026-2</pub-id></element-citation></ref><ref id="REF30"><label>30</label><element-citation publication-type="journal"><article-title>The vanishing bile duct syndrome in a child with Hodgkin disease</article-title><source>Med Pediatr Oncol</source><person-group>
<name name-style="western"><surname>Ozkan</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Yoruk</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Celkan</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Apak</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Yildiz</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Ozbay</surname><given-names>G</given-names></name>
</person-group><fpage>398</fpage><lpage>399</lpage><volume>36</volume><year>2001</year><pub-id pub-id-type="pmid">11241447</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/mpo.1096</pub-id></element-citation></ref><ref id="REF31"><label>31</label><element-citation publication-type="journal"><article-title>[Paraneoplastic vanishing bile duct syndrome in a case of Hodgkin's disease]</article-title><source>Ann Pathol</source><person-group>
<name name-style="western"><surname>Allory</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Métreau</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Zafrani</surname><given-names>E</given-names></name>
</person-group><fpage>52</fpage><lpage>55</lpage><volume>20</volume><year>2000</year><uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/10648987/" xmlns:xlink="http://www.w3.org/1999/xlink">https://pubmed.ncbi.nlm.nih.gov/10648987/</uri><pub-id pub-id-type="pmid">10648987</pub-id></element-citation></ref><ref id="REF32"><label>32</label><element-citation publication-type="journal"><article-title>Vanishing bile duct syndrome in Hodgkin's disease: case report</article-title><source>Sao Paulo Med J</source><person-group>
<name name-style="western"><surname>Rossini</surname><given-names>MS</given-names></name>
<name name-style="western"><surname>Lorand-Metze</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Oliveira</surname><given-names>GB</given-names></name>
<name name-style="western"><surname>Souza</surname><given-names>CA</given-names></name>
</person-group><fpage>154</fpage><lpage>157</lpage><volume>118</volume><year>2000</year><pub-id pub-id-type="pmid">11018850</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1590/S1516-31802000000500008</pub-id><pub-id pub-id-type="pmcid">PMC11175542</pub-id></element-citation></ref><ref id="REF33"><label>33</label><element-citation publication-type="journal"><article-title>Jaundice caused by the vanishing bile duct syndrome in a child with Hodgkin lymphoma</article-title><source>J Pediatr Hematol Oncol</source><person-group>
<name name-style="western"><surname>Yusuf</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Elias</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Hübscher</surname><given-names>SG</given-names></name>
</person-group><fpage>154</fpage><lpage>157</lpage><volume>22</volume><year>2000</year><pub-id pub-id-type="pmid">10779030</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/00043426-200003000-00014</pub-id></element-citation></ref><ref id="REF34"><label>34</label><element-citation publication-type="journal"><article-title>Fulminant hepatic failure as a presenting paraneoplastic manifestation of Hodgkin's disease</article-title><source>Eur J Gastroenterol Hepatol</source><person-group>
<name name-style="western"><surname>Dourakis</surname><given-names>SP</given-names></name>
<name name-style="western"><surname>Tzemanakis</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Deutsch</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Kafiri</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Hadziyannis</surname><given-names>SJ</given-names></name>
</person-group><fpage>1055</fpage><lpage>1058</lpage><volume>11</volume><year>1999</year><pub-id pub-id-type="pmid">10503847</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/00042737-199909000-00019</pub-id></element-citation></ref><ref id="REF35"><label>35</label><element-citation publication-type="journal"><article-title>Extrahepatic Hodgkin's disease with intrahepatic cholestasis: report of two cases</article-title><source>Oncology</source><person-group>
<name name-style="western"><surname>Yalçin</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Kars</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Sökmensüer</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Atahan</surname><given-names>L</given-names></name>
</person-group><fpage>83</fpage><lpage>85</lpage><volume>57</volume><year>1999</year><pub-id pub-id-type="pmid">10394130</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1159/000012005</pub-id></element-citation></ref><ref id="REF36"><label>36</label><element-citation publication-type="journal"><article-title>Cholestasis secondary to Hodgkin's disease: report of 2 cases of vanishing bile duct syndrome</article-title><source>Haematologica</source><person-group>
<name name-style="western"><surname>de Medeiros</surname><given-names>BC</given-names></name>
<name name-style="western"><surname>Lacerda</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Telles</surname><given-names>JE</given-names></name>
<name name-style="western"><surname>da Silva</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>de Medeiros</surname><given-names>CR</given-names></name>
</person-group><fpage>1038</fpage><lpage>1040</lpage><volume>83</volume><year>1998</year><uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/9864926/" xmlns:xlink="http://www.w3.org/1999/xlink">https://pubmed.ncbi.nlm.nih.gov/9864926/</uri><pub-id pub-id-type="pmid">9864926</pub-id></element-citation></ref><ref id="REF37"><label>37</label><element-citation publication-type="journal"><article-title>Resolution of paraneoplastic bile duct paucity following successful treatment of Hodgkin's disease</article-title><source>Hepatology</source><person-group>
<name name-style="western"><surname>Crosbie</surname><given-names>OM</given-names></name>
<name name-style="western"><surname>Crown</surname><given-names>JP</given-names></name>
<name name-style="western"><surname>Nolan</surname><given-names>NP</given-names></name>
<name name-style="western"><surname>Murray</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Hegarty</surname><given-names>JE</given-names></name>
</person-group><fpage>5</fpage><lpage>8</lpage><volume>26</volume><year>1997</year><pub-id pub-id-type="pmid">9214445</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep.510260101</pub-id></element-citation></ref><ref id="REF38"><label>38</label><element-citation publication-type="journal"><article-title>Intrahepatic cholestasis related to vanishing bile duct syndrome in Hodgkin's disease</article-title><source>J Pediatr Gastroenterol Nutr</source><person-group>
<name name-style="western"><surname>Gottrand</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Cullu</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Mazingue</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Nelken</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Lecomte-Houcke</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Farriaux</surname><given-names>JP</given-names></name>
</person-group><fpage>430</fpage><lpage>433</lpage><volume>24</volume><year>1997</year><uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/9144127/" xmlns:xlink="http://www.w3.org/1999/xlink">https://pubmed.ncbi.nlm.nih.gov/9144127/</uri><pub-id pub-id-type="pmid">9144127</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/00005176-199704000-00013</pub-id></element-citation></ref><ref id="REF39"><label>39</label><element-citation publication-type="journal"><article-title>Extrahepatic Hodgkin's disease and cholestasis</article-title><source>Am J Gastroenterol</source><person-group>
<name name-style="western"><surname>Warner</surname><given-names>AS</given-names></name>
<name name-style="western"><surname>Whitcomb</surname><given-names>FF</given-names></name>
</person-group><fpage>940</fpage><lpage>941</lpage><volume>89</volume><year>1994</year><uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/8198110/" xmlns:xlink="http://www.w3.org/1999/xlink">https://pubmed.ncbi.nlm.nih.gov/8198110/</uri><pub-id pub-id-type="pmid">8198110</pub-id></element-citation></ref><ref id="REF40"><label>40</label><element-citation publication-type="journal"><article-title>Intrahepatic cholestasis and biliary cirrhosis associated with extrahepatic Hodgkin's disease</article-title><source>Neth J Med</source><person-group>
<name name-style="western"><surname>Jansen</surname><given-names>PL</given-names></name>
<name name-style="western"><surname>van der Lelie</surname><given-names>H</given-names></name>
</person-group><fpage>99</fpage><lpage>102</lpage><volume>44</volume><year>1994</year><uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/8202211/" xmlns:xlink="http://www.w3.org/1999/xlink">https://pubmed.ncbi.nlm.nih.gov/8202211/</uri><pub-id pub-id-type="pmid">8202211</pub-id></element-citation></ref><ref id="REF41"><label>41</label><element-citation publication-type="journal"><article-title>Differential diagnosis of jaundice in lymphoma patients</article-title><source>Semin Liver Dis</source><person-group>
<name name-style="western"><surname>Birrer</surname><given-names>MJ</given-names></name>
<name name-style="western"><surname>Young</surname><given-names>RC</given-names></name>
</person-group><fpage>269</fpage><lpage>277</lpage><volume>7</volume><year>1987</year><pub-id pub-id-type="pmid">3317863</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1055/s-2008-1040582</pub-id></element-citation></ref><ref id="REF42"><label>42</label><element-citation publication-type="journal"><article-title>Intrahepatic cholestasis due to Hodgkin's disease. An elusive diagnosis</article-title><source>J Clin Gastroenterol</source><person-group>
<name name-style="western"><surname>Lieberman</surname><given-names>DA</given-names></name>
</person-group><fpage>304</fpage><lpage>307</lpage><volume>8</volume><year>1986</year><pub-id pub-id-type="pmid">3734366</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/00004836-198606000-00022</pub-id></element-citation></ref><ref id="REF43"><label>43</label><element-citation publication-type="journal"><article-title>Liver disease as presenting manifestation of Hodgkin's disease</article-title><source>Q J Med</source><person-group>
<name name-style="western"><surname>Trewby</surname><given-names>PN</given-names></name>
<name name-style="western"><surname>Portmann</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Brinkley</surname><given-names>DM</given-names></name>
<name name-style="western"><surname>Williams</surname><given-names>R</given-names></name>
</person-group><fpage>137</fpage><lpage>150</lpage><volume>48</volume><year>1979</year><uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/482587/" xmlns:xlink="http://www.w3.org/1999/xlink">https://pubmed.ncbi.nlm.nih.gov/482587/</uri><pub-id pub-id-type="pmid">482587</pub-id></element-citation></ref><ref id="REF44"><label>44</label><element-citation publication-type="journal"><article-title>Investigation of a patient with Hodgkin's disease and cholestasis</article-title><source>Gastroenterology</source><person-group>
<name name-style="western"><surname>Piken</surname><given-names>EP</given-names></name>
<name name-style="western"><surname>Abraham</surname><given-names>GE</given-names></name>
<name name-style="western"><surname>Hepner</surname><given-names>GW</given-names></name>
</person-group><fpage>145</fpage><lpage>147</lpage><volume>77</volume><year>1979</year><uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/447013/" xmlns:xlink="http://www.w3.org/1999/xlink">https://pubmed.ncbi.nlm.nih.gov/447013/</uri><pub-id pub-id-type="pmid">447013</pub-id></element-citation></ref><ref id="REF45"><label>45</label><element-citation publication-type="journal"><article-title>Cholestasis associated with extrabiliary Hodgkin's disease. Report of three cases and review of four others</article-title><source>Gastroenterology</source><person-group>
<name name-style="western"><surname>Perera</surname><given-names>DR</given-names></name>
<name name-style="western"><surname>Greene</surname><given-names>ML</given-names></name>
<name name-style="western"><surname>Fenster</surname><given-names>LF</given-names></name>
</person-group><fpage>680</fpage><lpage>685</lpage><volume>67</volume><year>1974</year><uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/4412423/" xmlns:xlink="http://www.w3.org/1999/xlink">https://pubmed.ncbi.nlm.nih.gov/4412423/</uri><pub-id pub-id-type="pmid">4412423</pub-id></element-citation></ref><ref id="REF46"><label>46</label><element-citation publication-type="journal"><article-title>Diagnosis of malignant lymphoma at laparotomy disclosing intrahepatic cholestasis</article-title><source>Acta Chir Scand</source><person-group>
<name name-style="western"><surname>Groth</surname><given-names>CG</given-names></name>
<name name-style="western"><surname>Hellström</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Hofvendahl</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Nordenstam</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Wengle</surname><given-names>B</given-names></name>
</person-group><fpage>186</fpage><lpage>189</lpage><volume>138</volume><year>1972</year><uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/4556480/" xmlns:xlink="http://www.w3.org/1999/xlink">https://pubmed.ncbi.nlm.nih.gov/4556480/</uri><pub-id pub-id-type="pmid">4556480</pub-id></element-citation></ref><ref id="REF47"><label>47</label><element-citation publication-type="journal"><article-title>Prolonged severe obstructive jaundice in Hodgkin's disease</article-title><source>Gastroenterology</source><person-group>
<name name-style="western"><surname>Juniper K</surname><given-names>Jr</given-names></name>
</person-group><fpage>199</fpage><lpage>204</lpage><volume>44</volume><year>1963</year><uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/13958086/" xmlns:xlink="http://www.w3.org/1999/xlink">https://pubmed.ncbi.nlm.nih.gov/13958086/</uri><pub-id pub-id-type="pmid">13958086</pub-id></element-citation></ref><ref id="REF48"><label>48</label><element-citation publication-type="journal"><article-title>Pathogenesis of jaundice in Hodgkin's disease</article-title><source>Arch Intern Med</source><person-group>
<name name-style="western"><surname>Bouroncle</surname><given-names>BA</given-names></name>
<name name-style="western"><surname>Old JW</surname><given-names>Jr</given-names></name>
<name name-style="western"><surname>Vazques</surname><given-names>AG</given-names></name>
</person-group><fpage>872</fpage><lpage>883</lpage><volume>110</volume><year>1962</year><pub-id pub-id-type="pmid">14014505</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1001/archinte.1962.03620240054009</pub-id></element-citation></ref><ref id="REF49"><label>49</label><element-citation publication-type="journal"><article-title>IKK1 and IKK2 cooperate to maintain bile duct integrity in the liver</article-title><source>Proc Natl Acad Sci U S A</source><person-group>
<name name-style="western"><surname>Luedde</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Heinrichsdorff</surname><given-names>J</given-names></name>
<name name-style="western"><surname>de Lorenzi</surname><given-names>R</given-names></name>
<name name-style="western"><surname>De Vos</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Roskams</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Pasparakis</surname><given-names>M</given-names></name>
</person-group><fpage>9733</fpage><lpage>9738</lpage><volume>105</volume><year>2008</year><pub-id pub-id-type="pmid">18606991</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1073/pnas.0800198105</pub-id><pub-id pub-id-type="pmcid">PMC2474544</pub-id></element-citation></ref><ref id="REF50"><label>50</label><element-citation publication-type="journal"><article-title>Pathology and pathogenesis of intrahepatic bile duct loss</article-title><source>J Hep Bil Pancr Surg</source><person-group>
<name name-style="western"><surname>Nakanuma</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Tsuneyama</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Harada</surname><given-names>K</given-names></name>
</person-group><fpage>303</fpage><lpage>315</lpage><volume>8</volume><year>2001</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s005340170002</pub-id><pub-id pub-id-type="pmid">11521175</pub-id></element-citation></ref><ref id="REF51"><label>51</label><element-citation publication-type="journal"><article-title>Pathophysiology of cholangiopathies</article-title><source>J Clin Gastroenterol</source><person-group>
<name name-style="western"><surname>Strazzabosco</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Fabris</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Spirli</surname><given-names>C</given-names></name>
</person-group><fpage>0</fpage><lpage>102</lpage><volume>39</volume><year>2005</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/01.mcg.0000155549.29643.ad</pub-id><pub-id pub-id-type="pmid">15758666</pub-id></element-citation></ref><ref id="REF52"><label>52</label><element-citation publication-type="journal"><article-title>Disappearing bile ducts: immunologic mechanisms</article-title><source>Hosp Pract</source><person-group>
<name name-style="western"><surname>Vierling</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Howell</surname><given-names>CD</given-names></name>
</person-group><fpage>141</fpage><lpage>150</lpage><volume>25</volume><year>1990</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.1080/21548331.1990.11703976</pub-id><pub-id pub-id-type="pmid">2115531</pub-id></element-citation></ref><ref id="REF53"><label>53</label><element-citation publication-type="journal"><article-title>Drug-induced cholestasis</article-title><source>Expert Opin Drug Saf</source><person-group>
<name name-style="western"><surname>Velayudham</surname><given-names>LS</given-names></name>
<name name-style="western"><surname>Farrell</surname><given-names>GC</given-names></name>
</person-group><fpage>287</fpage><lpage>304</lpage><volume>2</volume><year>2003</year><pub-id pub-id-type="pmid">12904107</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1517/14740338.2.3.287</pub-id></element-citation></ref><ref id="REF54"><label>54</label><element-citation publication-type="journal"><article-title>A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel</article-title><source>NPJ Breast Cancer</source><person-group>
<name name-style="western"><surname>Piawah</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Hyland</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Umetsu</surname><given-names>SE</given-names></name>
<name name-style="western"><surname>Esserman</surname><given-names>LJ</given-names></name>
<name name-style="western"><surname>Rugo</surname><given-names>HS</given-names></name>
<name name-style="western"><surname>Chien</surname><given-names>AJ</given-names></name>
</person-group><fpage>17</fpage><volume>5</volume><year>2019</year><pub-id pub-id-type="pmid">31240240</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/s41523-019-0112-z</pub-id><pub-id pub-id-type="pmcid">PMC6570645</pub-id></element-citation></ref><ref id="REF55"><label>55</label><element-citation publication-type="journal"><article-title>Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis</article-title><source>Nat Clin Pract Gastroenterol Hepatol</source><person-group>
<name name-style="western"><surname>Beuers</surname><given-names>U</given-names></name>
</person-group><fpage>318</fpage><lpage>328</lpage><volume>3</volume><year>2006</year><pub-id pub-id-type="pmid">16741551</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/ncpgasthep0521</pub-id></element-citation></ref><ref id="REF56"><label>56</label><element-citation publication-type="journal"><article-title>Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events</article-title><source>J Clin Exp Hematop</source><person-group>
<name name-style="western"><surname>Ishitsuka</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Yokoyama</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Baba</surname><given-names>N</given-names></name>
<etal/>
</person-group><fpage>154</fpage><lpage>157</lpage><volume>62</volume><year>2022</year><pub-id pub-id-type="pmid">35831099</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.3960/jslrt.21035</pub-id><pub-id pub-id-type="pmcid">PMC9635035</pub-id></element-citation></ref><ref id="REF57"><label>57</label><element-citation publication-type="journal"><article-title>Single-agent brentuximab as bridging therapy for Hodgkin lymphoma patients with hepatic impairment</article-title><source>Clin Lymphoma Myeloma Leuk</source><person-group>
<name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Petrasek</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Sen</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Gopal</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Naina</surname><given-names>HV</given-names></name>
</person-group><fpage>0</fpage><lpage>4</lpage><volume>16</volume><year>2016</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.clml.2015.11.015</pub-id><pub-id pub-id-type="pmid">26775723</pub-id></element-citation></ref><ref id="REF58"><label>58</label><element-citation publication-type="journal"><article-title>Hodgkin lymphoma associated vanishing bile duct syndrome treated successfully with a brentuximab based regimen</article-title><source>BMJ Case Rep</source><person-group>
<name name-style="western"><surname>Morgan</surname><given-names>JD</given-names></name>
<name name-style="western"><surname>Weishar</surname><given-names>RC</given-names></name>
<name name-style="western"><surname>Kwok</surname><given-names>RM</given-names></name>
<name name-style="western"><surname>Lieuw</surname><given-names>KM</given-names></name>
</person-group><fpage>0</fpage><volume>16</volume><year>2023</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/bcr-2023-257211</pub-id><pub-id pub-id-type="pmcid">PMC10668144</pub-id><pub-id pub-id-type="pmid">37989332</pub-id></element-citation></ref></ref-list></back></article>